Research theme for competitive and other funds (1):
2001 - 2002 臍帯血由来樹状細胞とCMV特異的ペプチドを用いたCMVワクチンの開発
Papers (46):
Takaaki Konuma, Akira Tomonari, Jun Ooi, Hitomi Nagayama, Toshiro Kawakita, Seiko Kato, Masamichi Isobe, Maki Monna-Oiwa, Arinobu Tojo, Yasuhito Nannya, et al. Thyrotoxicosis after unrelated cord blood transplantation for adults. Annals of hematology. 2022
Takaaki Konuma, Jun Ooi, Hitomi Nagayama, Akira Tomonari, Nobuhiro Tsukada, Seiko Kato, Toshiro Kawakita, Masamichi Isobe, Maki Monna-Oiwa, Arinobu Tojo, et al. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. Annals of Hematology. 2021
R Watanabe, S Okamoto, T Mori, H Nishida, Y Tsukada, N Sato, H Nagayama, N Takayama, Y Ikeda. Late-onset non-infectious pulmonary complications after allogeneic stem cell transplantation (SCT). BONE MARROW TRANSPLANTATION. 2002. 29. S178-S178
T Iguchi, S Okamoto, T Mori, R Watanabe, N Sato, H Nagayama, N Takayama, Y Ikeda. Risk factors of acute graft-versus-host disease (AGVHD) after allogeneic bone marrow transplantation using an matched unrelated donor (MUD) and prophylaxis with taclorimus (FK506) and methotrexate (MTX). BONE MARROW TRANSPLANTATION. 2002. 29. S172-S173
Y Tsukada, S Okamoto, T Mori, R Watanabe, T Iguchi, R Yamazaki, N Sato, H Nagayama, N Takayama, Y Ikeda. Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. BONE MARROW TRANSPLANTATION. 2002. 29. S162-S162